Literature DB >> 24976287

Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis.

Mehmet Agilli1, Fevzi N Aydin, Ibrahim Aydin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24976287      PMCID: PMC4067920          DOI: 10.4103/1319-3767.133039

Source DB:  PubMed          Journal:  Saudi J Gastroenterol        ISSN: 1319-3767            Impact factor:   2.485


× No keyword cloud information.
Sir, We have read with great interest the published article by Atamer et al., entitled “Evaluation of Paraoxonase, Malondialdehyde, and Lipoprotein Levels in Patients with Asymptomatic Cholelithiasis”.[1] Authors have found lower serum paraoxonase and higher serum malondialdehyde (MDA) levels in patients with asymptomatic cholelithiasis. However, we think that some more points should be discussed. The authors measured C-reactive protein (CRP) to demonstrate inflammatory status in the body. If other tests showing inflammatory status as erythrocyte sedimentation rate and complete blood count were assigned in addition to CRP, determining the study groups could be more reliable.[2] Moselhy et al., reported the inaccuracy for thiobarbituric acid reactive substances (TBARS) assays on quantifying MDA, and they stated that TBARS approach may limit the likelihood of detecting true differences in the level of lipid peroxidation in clinical studies.[3] The poor specificity of TBARS assays could lead to an overestimation of MDA levels in human plasma.[3] If a chromatographic assay that is accepted to have satisfactory analytic performance to determine MDA levels as a true indicator of lipid peroxidation in biological matrices was employed in this study, interpretation of the results would have been more reliable. There is an inconsistency between Table 1 and Table 2 on aspartate aminotransaminase (AST) and gamma-glutamyl transferase (GGT) levels of cholelithiasis group. Both parameters are lower in glucose >100 mg/dL and glucose <100 mg/dL groups of cholelithiasis in Table 2 than whole cholelithiasis group in Table 1, which could not be possible. Although there were no significant differences on these parameters between the control and the cholelithiasis groups according to Table 1, these data cause confusion and loss of reliability of the study. Also other tables should be revised because of similar errors.
Table 1

Comparison of clinical and biochemical parameters between healthy control and cholelithiasis group

Table 2

Comparison of age, body mass index and laboratory parameters between subjects with cholelithiasis who have fasting blood glucose >100 mg/dL and <100 mg/dL

Comparison of clinical and biochemical parameters between healthy control and cholelithiasis group Comparison of age, body mass index and laboratory parameters between subjects with cholelithiasis who have fasting blood glucose >100 mg/dL and <100 mg/dL The 2001 National Cholesterol Education Program Adult Treatment Panel III report about metabolic syndrome diagnostic criteria include abdominal obesity, hypertriglyceridemia, decreased high-density lipoprotein cholesterol, high blood pressure, and hyperglycemia.[4] As it is known, metabolic syndrome is a risk factor for cholelithiasis.[5] In this study, cholelithiasis group consists of individuals, majority of whom have one or more metabolic syndrome criteria. In this regard, it is questionable if the findings of this study rely on cholelithiasis or metabolic syndrome itself. Namely, it is the main point whether cholelithiasis is a cause for these results or a result of metabolic syndrome beside other findings. In this view, explanation of these concerns would certainly provide the readers clearer information.
  5 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Negative C-reactive protein in children with bacterial infection.

Authors:  T Kono; M Otsuka; M Ito; M Misawa; A Hoshioka; M Suzuki; T Migita; I Seki
Journal:  Pediatr Int       Date:  1999-10       Impact factor: 1.524

3.  The metabolic syndrome is associated with complicated gallstone disease.

Authors:  Naim Ata; Metin Kucukazman; Bunyamin Yavuz; Hakan Bulus; Kursad Dal; Derun Taner Ertugrul; Ahmet Arif Yalcin; Mehmet Polat; Numan Varol; Kadir Okhan Akin; Aral Karabag; Yasar Nazligul
Journal:  Can J Gastroenterol       Date:  2011-05       Impact factor: 3.522

4.  A specific, accurate, and sensitive measure of total plasma malondialdehyde by HPLC.

Authors:  Hamdy F Moselhy; Raymond G Reid; Saeed Yousef; Susanne P Boyle
Journal:  J Lipid Res       Date:  2012-12-20       Impact factor: 5.922

5.  Evaluation of paraoxonase, malondialdehyde, and lipoprotein levels in patients with asymptomatic cholelithiasis.

Authors:  Aytac Atamer; Ayse O Kurdas-Ovunc; Atakan Yesil; Yildiz Atamer
Journal:  Saudi J Gastroenterol       Date:  2014 Jan-Feb       Impact factor: 2.485

  5 in total
  1 in total

1.  Response to: Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis.

Authors:  Aytac Atamer; Yildiz Atamer; Ahmet S Can
Journal:  Saudi J Gastroenterol       Date:  2016 Jan-Feb       Impact factor: 2.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.